Publications

Activity of Linezolid when Tested Against Contemporary European Bacterial Clinical Isolates (2015), Lead author: Flamm RK, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Analysis of the activity of telavancin tested against a global collection of Staphylococcus aureus clinical isolates responsible for documented hospital-acquired pneumonia (2014), Lead author: Mendes RE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Oritavancin activity tested against European staphylococcal clinical isolates and resistant subsets inlcuding those with reduced susceptibility to daptomycin, teicoplanin or vancomycin (2010-2014), Lead author: Mendes RE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

WCK 4282 (Cefepime-Tazobactam) MIC Quality Control Ranges Using a Multi-Laboratory Study Design, Lead author: Ross JE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Omadacycline Activity Tested Against European Bacterial Isolates from a Combined 2010-2011 Global Surveillance Program, Lead author: Flamm RK, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Delafloxacin activity tested against bacterial pathogens from 44 medical centres in Europe and Israel (2014), Lead author: Flamm RK, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

The Activity of Tedizolid against Gram-positive Pathogens Isolated from Patients in Medical Centres in Europe, Turkey and Israel: 2014 Surveillance, Lead author: Farrell DJ, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

WCK4282 (High-Dose Cefepime-Tazobactam) Antimicrobial Activity against Gram-negative Organisms from United States and Latin America medical Centers (2014), Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients. by Flamm RK, Nichols WW, Sader HS, Farrell DJ and Jones RN published in Int. J. Antimicrob. Agents. 2016; 47 (3): 235-242

Results from oritavancin resistance surveillance programs (2011-2014): Clarification for using vancomycin as a surrogate to infer oritavancin susceptibility. by Jones RN, Moeck G, Arhin FF, Dudley MN, Rhomberg PR and Mendes RE published in Antimicrob. Agents. Chemother. 2016; 60 (5): 3174-3177

Activity of fusidic acid tested against staphylococci isolated from patients in United States medical centers during 2014. by Farrell DJ, Mendes RE, Castanheira M and Jones RN published in Antimicrob. Agents Chemother. 2016; 60 (6): 3827-3831

Ceftaroline activity tested against viridans group streptococci from US hospitals. by Sader HS, Rhomberg PR, Castanheira M, Farrell DJ, Flamm RK, Mendes RE and Jones RN. published in Diagn. Microbiol. Infect. Dis. 2016; 84 (3): 232-235

Linezolid surveillance results for the United States (LEADER Surveillance Program 2014). by Flamm RK, Mendes RE, Hogan PA, Streit JM, Ross JE and Jones RN. published in Antimicrob. Agents Chemother. 2016; 60 (4): 2273-2280

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): Evolving resistance mechanisms with stable susceptibility rates. by Mendes RE, Hogan PA, Jones RN, Sader HS and Flamm RK published in J. Antimicrob. Chemother. 2016; 71 (7):1860-1865

Dalbavancin activity when tested against Streptococcus pneumoniae isolated in medical centers on six continents (2011-2014). by Jones RN, Schuchert JE and Mendes RE. published in Antimicrob. Agents. Chemother. 2016; 60 (6): 3419-3425

Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014). by Jones RN, Rhomberg PR and Mendes RE. published in Diag. Microbio. Infect. Dis. 2016; 86 (2): 249-251

Antimicrobial activities of ceftaroline and comparator agents against bacterial organisms causing bacteremia in patients with skin and skin structure infections in U.S. Medical Centers, 2008 to 2014. by Sader HS, Flamm RK, Mendes RE, Farrell DJ and Jones RN published in Antimicrob. Agents. Chemother. 2016; 60 (4): 2558-2563

Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals. by Sader HS, Farrell DJ, Flamm RK, Streit JM, Mendes RE and Jones RN. published in Diagn. Microbiol. Infect. Dis. 2016; 85 (1): 80-84

Antifungal susceptibility patterns of a global collection of fungal isolates: Results of the SENTRY Antifungal Surveillance Program (2013). by Castanheira M, Messer SA, Rhomberg PR and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2016; 85 (2):200-204

Results from the Solithromycin International Surveillance Program (2014). by Farrell DJ, Flamm RK, Sader HS and Jones RN. published in Antimicrob. Agents. Chemother. 2016; 60 (6): 3662-3668, 2016

In vitro activity of ceftazidime-avibactam against contemporary Pseudomonas aeruginosa isolates from United States medical centers by Census region (2014). by Huband MD, Castanheira M, Flamm RK, Farrell DJ, Jones RN and Sader HS. published in Antimicrob. Agents. Chemother. 2016; 60 (4): 2537-2541

Performance of BD Max StaphSR for screening of methicillin-resistant Staphylococcus aureus isolates among a contemporary and diverse collection from 146 institutions located in nine U.S. Census Regions: Prevalence of mecA dropout mutants. by Mendes RE, Watters AA, Rhomberg PR, Farrell DJ and Jones RN. published in J. Clin. Microbiol. 2016; 54 (1): 204-207

Nosocomial Candidiasis: Antifungal stewardship and the importance of rapid diagnosis. by Pfaller MA and Castanheira M published in Med. Mycol. 2016; 54 (1): 1-22

Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13). by Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS and Jones RN. published in J. Antimicrob. Chemother. 2016; 71 (1): 276-278

Mechanisms of resistance, clonal expansion, and increasing prevalence of Acinetobacter baumannii strains displaying elevated tigecycline MIC values in Latin America. by Costello SE, Gales AC, Morfin-Otero R, Jones RN and Castanheira M published in Microb. Drug Resist. 2016; 22 (4): 253-258

Klebsiella pneumoniae from a New York City hospital belonging to ST258 and carrying blaKPC-2- and blaVIM-4-encoding genes. by Castanheira M, Deshpande LM, Mills JC, Jones RN, Soave R, Jenkins SG and Schuetz AN published in Antimicrob. Agents. Chemother. 2016; 60 (3): 1924-1927

In vitro activity of ceftolozane-tazobactam against anaerobic organisms identified during the ASPECT-cIAI study. by Armstrong ES, Farrell DJ, Palchak M and Steenbergen JN published in Antimicrob. Agents. Chemother. 2016; 60 (1): 666-668

In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. by Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M and Yamano Y published in J. Antimicrob. Chemother. 2016; 71 (3): 670-677

Beta-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: Clinical efficacies analyzed against subsets of molecularly characterized isolates. by Mendes RE, Castanheira M, Gasink L, Stone GG, Nichols WW, Flamm RK and Jones RN. published in Antimicrob. Agents. Chemother. 2015; 60 (3): 1328-1335

Antimicrobial activity of ceftaroline tested against Staphylococcus aureus from surgical skin and skin structure infections in US Medical Centers. by Sader HS, Farrell DJ, Flamm RK and Jones RN. published in Surg. Infect. (Larchmt) 2016; 17 (4): 443-447

Oritavancin activity tested against molecularly-characterized staphylococci and enterococci displaying elevated linezolid MIC results. by Mendes RE, Farrell DJ, Sader HS, Flamm RK and Jones RN. published in Antimicrob. Agents. Chemother. 2016; 60 (6): 3817-3820

Contemporary Analysis of Oritavancin Activity Against S. aureus Responsible for Invasive Community- and Hospital-associated Infections in the USA (2013-2014), Lead author: Mendes Re, presented at ID Week, October 7-11, 2015, San Diego, CA

Report of Linezolid Activity from the LEADER Program for 2014: Monitoring Resistance Trends and Mechanisms, Lead author: Flamm RK, presented at ID Week, October 7-11, 2015, San Diego, CA

Comparative Evaluation of the Antimicrobial Susceptibility Patterns of Community-and Hospital-Acquired MRSA from USA Hospitals by Site of Infection: Results from AWARE (2012-2014), Lead author: Sader HS, presented at ID Week, October 7-11, 2015, San Diego, CA

The Actvity of Tedizolid against Gram-positive Pathogens from USA Medical Centers: 2014 Surveillance, Lead author: Farrell DJ, presented at ID Week, October 7-11, 2015, San Diego, CA

Analysis of Telavancin Activity Against a USA Collection of S. aureus Clinical Isolates Causing HAP (2013-2014), Lead author: Mendes RE, presented at ID Week, October 7-11, 2015, San Diego, CA

Activity of Ceftaroline Organisms Causing Bacteremia in Patients with SSSI in USA Medical Centers (2008-2014), Lead author: Sader HS, presented at ID Week, October 7-11, 2015, San Diego, CA

Activity of Ceftazidime-avibactam and Comparator Agents tested against Gram-negative Organisms Isolated from Urinary tract infections (UTI): Results from the International Network for Optimal Resistance Monitoring (INFORM) Program, Lead author: Sader HS, presented at ID Week, October 7-11, 2015, San Diego, CA

In Vitro Antibacterial Activity of Meropenem/RPX709, (a Carpabenem/ß-lactamase Inhibitor Combination) Against Contemporary Enterobacteriaceae Isolated from Intra-abdominal and Urinary Tract Infections in the United States, Lead author: Castanheira M, presented at ID Week, October 7-11, 2015, San Diego, CA

In Vitro Activity of Tedizolid against Streptococci and Enterococci Isolated from the United States and Europe in 2014, Lead author: Farrell DJ, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Update of Telavancin in vitro Activity Against a USA collection of Gram-Positive Clinical Isolates (2014) Causing Skin and Skin Structure Infections, Lead author: Mendes RE, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Ceftobiprole Activity When Tested Against Clinical Bacterial Pathogens from Europe, Turkey and Israel 2014, Lead author: Farrell DJ, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Activity of Omadacycline Tested against Enterobacteriaceae Causing Urinary Tract Infections from a Global Surveillance Porgram (2014), Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Activity of Omadacycline Tested against Streptococcus pneumoniae from a Global Surveillance Porgram (2014), Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Activity of Omadacycline Tested Against S. aureus from a Global Surveillance Program (2014), Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Performance of BD MAX™ StaphSR against S. aureus Clinical Isolates from the 9 USA Census Regions, Lead author: Mendes RE, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Activity of Solithromycin Against Pathogens Associated with CABP: Global Surveillance Results from 2014, Lead author: Farrell DJ, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

In Vitro Activity of Pexiganan Tested Against Pathogens with Elevated MICs to Topical Antimicrobials, Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Solithromycin MIC and Disk Diffusion Quality Control Ranges, a CLSI Multi-Laboratory M23-A3 Study Design, Lead author: Ross JE, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Activity of a Long-acting Echincandin (CD101) and Comparator Antifungal Agents against Contemporary Invasive Fungal Isolates, Lead author: Castanheira M, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA